The effect of U2AF1 mutation on erythroid differentiation and sensitivity to demethylation drug treatment.

Yuankai Liu, Xiu Li, Haitao Wang, Qiong Yang

Abstract read

In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuankai LiuBeijing Key Laboratory of Gene Resource and Molecular Development, Beijing Normal University, Beijing, China.

Xiu LiBeijing Key Laboratory of Gene Resource and Molecular Development, Beijing Normal University, Beijing, China.

Haitao WangSenior Department of Hematology, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100071, China. ws_ht@126.com.

Qiong YangBeijing Key Laboratory of Gene Resource and Molecular Development, Beijing Normal University, Beijing, China. yangqiong@bnu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is a group of blood disorders characterized by impaired maturation of erythroid cells. Mutations in the U2 small nuclear RNA auxiliary factor 1 (U2AF1) gene, particularly S34 (S34F/Y) and Q157 (Q157P/R), have been identified in 5-10% of MDS patients. By analyzing U2AF1 expression in hematopoietic stem progenitor cells and different blood cells in the GEO database, we have found the expression pattern of U2AF1 showed a significant stage specificity during normal erythropoiesis. To explore the specific impact of U2AF1 alterations on cellular function, we transduced K562 cells with lentivirus carrying four different types of U2AF1 mutants. Our results showed that these mutations significantly inhibited the growth of K562 cells. Mutations at the S34 sites (S34F and S34Y) reduced the mRNA expression levels of erythroid-related transcription factors GATA1, NF-E2, EKLF, and GFI-1B. The proportion of cells with CD71

Indexed as

AzacitidineCell DifferentiationErythroid CellsMutationMyelodysplastic SyndromesSplicing Factor U2AFDNA MethylationErythropoiesisFemaleHumansK562 CellsMaleMiddle AgedAzacitidineSplicing Factor U2AFU2AF1 protein, humanDemethylation drugErythroid differentiationMDSSpliceosome gene mutationsU2AF1

Identifiers

PMID40886238

DOI10.1007/s12032-025-02956-2

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.